

IN THE U.S. PATENT AND TRADEMARK OFFICE

11000 U.S. PTO  
09/955933  
09/20/01

Applicant(s): COHEN, Luba

Application No.:

Group:

Filed: September 20, 2001

Examiner:

For: LICORICE EXTRACT FOR USE AS MEDICAMENT

L E T T E R

Assistant Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

September 20, 2001  
2786-0191P

Sir:

Under the provisions of 35 USC 119 and 37 CFR 1.55(a), the applicant hereby claims the right of priority based on the following application(s):

<u>Country</u>	<u>Application No.</u>	<u>Filed</u>
Israel	138603	09/21/00

A certified copy of the above-noted application(s) is(are) attached hereto.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. 1.16 or under 37 C.F.R. 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By: 

MARC S. WEINER  
Reg. No. 32,181  
P. O. Box 747

Falls Church, Virginia 22040-0747

Attachment  
(703) 205-8000  
/cqc



מדינת ישראל  
STATE OF ISRAEL

Ministry of Justice  
Patent Office

משרד המשפטים  
לשכת הפטנטים

This is to certify that annexed  
hereto is a true copy of the  
documents as originally  
deposited with the patent  
application of which  
particulars are specified on the  
first page of the annex.

זאת לתעודה כי רצופים  
בזה העתקים נכונים של  
המסמכים שהופקדו  
לכתחילה עם הבקשה  
לפטנט לפי הפרטים  
הרשומים בעמוד הראשון  
של הנספח.

This 09-09-2001 היום

מ. ל. לוי  
ממונה על הבוחנים  
רשם הפטנטים  
Commissioner of Patents

נתאשר  
Certified

BSUB 003-205-8000  
COHEN, Luba  
2786-0191P  
September 20, 2001  
181



לשימוש הלשכה  
For Office Use

מספר: Number	38603
תאריך: Date	21-09-2000
הוקדם/נדחה: Ante/Post-dated	

**בקשה לפטנט**  
Application For Patent

אני, (שם המבקש, מענו ולגבי גוף מאגדת מקום התאגדותו)  
I, (Name and address of applicant, and in case of body corporate-place of incorporation)

רדי-מיייד 37 (1999) בע"מ, חברה ישראלית, מרחוב ויסוצקי 4, תל אביב 62502, ישראל  
Ready-Made 37 (1999) Ltd, Israeli company, of 4, Wissotzky Street, Tel-Aviv 62502, ISRAEL

שמה הוא  
of an invention the title of which is

Right of Law

הדין

בעל אמצאה מכח  
Owner, by virtue of

מיצוי ליקוריס לשימוש כתרופה

Licorice extract for use as a medicament

(בעברית)  
(Hebrew)

(באנגלית)  
(English)

Hereby apply for a patent to be granted to me in respect thereof.

מבקש בזאת כי ינתן לי עליה פטנט

* בקשת חלוקה Application of Division		* בקשת פטנט מוסף Appl. for Patent of Addition		* דרישת דין קדימה Priority Claim		
מבקשת פטנט from application		* לבקשה/לפטנט to Patent/Appl.		מספר/סימן Number/Mark	תאריך Date	מדינת האיגוד Convention Country
No.	מס'	No.	מס'			
Dated	מיום	Dated	מיום			
P.O.A.:		* יפוי כח:				
עד יוגש						
המען למסירת מסמכים בישראל Address for Service in Israel						
REINHOLD COHN AND PARTNERS Patent Attorneys P.O.B. 4060, Tel-Aviv				C. 123927		
חתימת המבקש Signature of Applicant				היום This		
For the Applicants, REINHOLD COHN AND PARTNERS By: —				2000 שנת Year		
S. Hirsch				September of		
				20 of		
				לשימוש הלשכה For Office Use		

טופס זה כשהוא מוטבע בחותם לשכת הפטנטים ומושלם במספר ובתאריך ההגשה, הנו אישור להגשת הבקשה שפרטיה רשומים לעיל.  
This form, impressed with the Seal of the Patent Office and indicating the number and date of filing, certifies the filing of the application the particulars of which are set out above.

\* מחק את המיותר  
Delete whatever is inapplicable

מיצוי ליקוריס לשימוש כתרופה

Licorice extract for use as a medicament

Ready-Made 37 (1999) Ltd

רדי-מייד 37 (1999) בע"מ

C. 123927

## LICORICE EXTRACT FOR USE AS A MEDICAMENT

### FIELD OF THE INVENTION

This invention relates to pharmaceutical and nutraceutical compositions that contain licorice extract.

### BACKGROUND OF THE INVENTION

5        Licorice roots, which consist of the dried unpeeled roots of *Glycyrrhiza* are widely used in Asia as a sweetener and a spice. Licorice root has also been used medically for more than 3000 years, and a wide range of therapeutic uses have been ascribed thereto. Glycyrrhizinic acid, contained in licorice root, was attributed several pharmacological activities, such as anti-bacterial, anti-viral,  
10    anti-inflammatory, anti-allergic and anti-hepatotoxic activity. However, the traditional licorice extracts, and in particular glycyrrhizinic acid, were also shown to cause hypertension, and this severe side effect considerably reduced their use.

      Recently, Fuhrman et al. showed that a certain ethanolic extract of licorice is useful in inhibition of LDL oxidation. [Fuhrman et al., *The American Journal of*  
15    *Clinical Nutrition*, 66, pp. 267-75 (1997)]. This very same study, however, did not find that the consumption of that licorice extract by humans causes any significant influence on plasma cholesterol, LDL concentration, or any other medical characteristic examined.

### 20    SUMMARY OF THE INVENTION

      The present invention is based on the finding that a licorice extract similar to that used by Fuhrman et al. is useful in decreasing in human subjects the blood

pressure, blood glucose concentration, blood total cholesterol and LDL levels, and blood tryglicerides and VLDL concentration. Other findings that led to the present invention are that licorice extract consumption reduces the susceptibility of human blood serum LDL to two heterogenic modifications, namely: retention and aggregation. The licorice extract that was found to bring to these results is characterized by being water-insoluble and free from glycyrrhizinic acid.

In the following, blood pressure, blood cholesterol and LDL levels, blood tryglicerides and VLDL concentration, blood glucose concentration, and serum LDL susceptibility to retention and aggregation will be named generally "risk factors", since they are related to the risk of cardiovascular diseases.

Thus, the present invention provides a pharmaceutical or neutraceutical preparation for lowering at least one of the following risk factors: blood pressure, glucose concentration, blood cholesterol and LDL levels, blood tryglicerides and VLDL concentration, and serum LDL susceptibility to retention and aggregation, said preparation comprising licorice extract, which is water-insoluble and free from glycyrrhizinic acid.

Preferably, the pharmaceutical or neutraceutical composition of the invention is for lowering at least one of the following risk factors: blood pressure, blood glucose concentration, susceptibility of serum LDL to retention, and susceptibility of serum LDL to aggregation.

Most preferably the pharmaceutical or neutraceutical composition of the present invention is for lowering at least one of the following risk factors: blood pressure and glucose concentration.

According to another aspect, the present invention provides licorice extract, which is water-insoluble and free from glycyrrhizinic acid, for use in the prevention and/or treatment of at least one of the following conditions and diseases: inflammation, hypertension, diabetes, chronic renal failure, atherosclerotic diseases, carotid artery stenosis, coronary heart diseases, hypercholesterolemia, and hypertriglyceridemia.

Preferably, the use according to the invention is in the prevention and/or treatment of at least one of the following conditions: hypertension, diabetes, chronic renal failure, and inflammation.

5 The term *prevention* means reduction of the risk of having the condition or the disease, while the term *treatment* means slowing down the development of the condition or the disease or relieving at least one symptom thereof.

The invention also provides the use of licorice extract, which is free from glycyrrhizinic acid, in the preparation of a medicament for preventing or treating any of the conditions and diseases mentioned above.

10 The invention also provides a pharmaceutical or nutraceutical immuno-potentiator comprising a licorice extract, which is water-insoluble and free from glycyrrhizinic acid. The immuno-potentiating value of the extract may be deduced from its ability to reduce the susceptibility of human serum to LDL aggregation.

15 According to another aspect of the present invention there is provided a method for treating hypertension, diabetes, chronic renal failure, cardiovascular diseases, carotid artery stenosis, atherosclerotic diseases, and coronary heart diseases in a subject, comprising administering to said subject a therapeutically effective amount of a licorice extract that is water-insoluble and free of  
20 glycyrrhizinic acid.

Preferably, the method of the invention is for treating hypertension, diabetes, and chronic renal failure, and most preferably hypertension.

## BRIEF DESCRIPTION OF THE DRAWINGS

25 In order to understand the invention and to see how it may be carried out in practice, a detailed description of some experimental results will now be given, by way of non-limiting example only, with reference to the accompanying drawings, in which:

Fig. 1 is a graph showing the effect of licorice extract on systolic blood pressure;

Fig. 2 is a graph showing the effect of licorice extract on diastolic blood pressure;

5 Fig. 3 is a graph showing the effect of licorice extract on cholesterol levels in the blood;

Fig. 4 is a graph showing the effect of licorice extract on LDL levels in the blood;

10 Fig. 5 is a graph showing the effect of licorice extract on HDL levels in the blood;

Fig. 6 is a graph showing the effect of licorice extract on VLDL levels in the blood;

Fig. 7 is a graph showing the effect of licorice extract on triglycerides levels in the blood;

15 Fig. 8 is a graph showing the effect of licorice extract on glucose levels in the blood.

Fig. 9 is a graph showing the effect of licorice extract on serum susceptibility to LDL retention.

20 Fig. 10 is a graph showing the effect of licorice extract on serum susceptibility to LDL aggregation.

## DETAILED DESCRIPTION OF THE INVENTION

25 1 kg raw Licorice root was ground to obtain slices of about 0.5 to 2 cm length and dried. The dry ground root was steeped in 5 liter absolute ethanol at room temperature, stirred for 5 hours, and filtered. The ethanol was evaporated and the resultant residue was dried to constant mass at 85°C to give 30 gr of product.



The product, hereinafter referred to as *licorice extract*, was then pulverized to give fine reddish brown powder that is practically insoluble in water and with no traceable amount of glycyrrhizinic acid. The powder was conventionally encapsulated and given to the volunteers in the experiment described bellow.

5       Some notes on the above procedure are in place: licorice extracts of similar health promoting effects, even if in other concentrations and required dosages, may be obtained also with other extracting solutions like acetone, ethyl acetate or hexane. Ethanol was found by the inventors to give the extract with the highest yield and activity. In any case, it is important that the raw material is dried before  
10       the extraction and that the extraction is carried out in a dry solvent. Otherwise, the product will be somewhat water-soluble, and obtaining the extract of the invention will necessitate expensive and complicated processes for removing the water-soluble portions of the extract.

Twelve adult hypercholesterolemic patients consumed for one month 100mg  
15       licorice extract per day. The risk factors defined above were measured in these patients before and after licorice consumption, and compared. The results are shown in Figures 1 to 10.

In Figures 1 to 8 and 10 the X axis values are of the measured risk factor before licorice consumption, the Y axis values are of the measured risk factor after  
20       licorice consumption, and the straight line is the equation  $Y=X$ . Every point bellow this line represents (at least one) patient in whom the measured risk factor after licorice consumption was lower then before.

Fig. 1 shows that ten out of the twelve patients showed a decrease in the  
25       systolic blood pressure after licorice consumption. Fig. 2 shows that the diastolic blood pressure of the same 12 patients was not significantly effected by the licorice consumption.

Lowering the blood pressure may be useful in reducing the risk to atherosclerotic diseases and is desirable in the treatment of a variety of disease and

conditions, e.g. cardiovascular diseases, chronic renal failure, carotid artery stenosis, and coronary heart diseases, in patients with high blood pressure.

The graphs in Figs. 3 and 4 show the cholesterol and LDL levels (measured in mg/dl) in the same patients before and after consuming licorice extract. As shown in the figures, after consumption of licorice extract the cholesterol level decreased in 10 out of 12 patients and the LDL decreased in 11 out of 12. Fig. 5 shows that no significant change of HDL levels was detected after consumption of the licorice extract. As may be deduced from the results shown in Figs. 3, 4, and 5 most of the decrease in cholesterol is due to a decrease in the LDL level, not in HDL level. Lowering the cholesterol and LDL levels may effect hypercholesterolemic patients to reduce the risk of atherosclerotic diseases and is desirable in the treatment of cardiovascular diseases, chronic renal failure, carotid artery stenosis, and coronary heart diseases in these patients. The simultaneous lowering of the LDL levels and blood pressure that the licorice extract exhibits may be especially beneficial to patients that suffer from both high blood pressure and high LDL levels. On the other hand it makes the licorice extract effective to a wide population, including both hypertension and hypercholesterolemic patients.

Figs. 6 and 7 show that after the licorice consumption, all the twelve patients had lower blood concentration of triglycerides than they had prior to this consumption, and 10 out of 12 had lower VLDL blood concentration. Furthermore, the average decrease in the triglycerides level was about 20%, which is remarkable for one month treatment. Lowering the triglycerides and the VLDL concentrations may have beneficial effects as were already mentioned before, and widens even more the population that may benefit from licorice extract consumption. It may also be useful as a single medication to help people that suffer from more than one of the risk factors: high blood pressure, high cholesterol and LDL levels, and high triglyceride concentration.

Fig. 8 shows the effect of licorice extract on blood-glucose. The figure shows that in 10 out of the twelve patients the blood-glucose decreased. Lowering the blood-glucose may reduce the risk to diabetes and its complications, including,

for instance, chronic renal failure, blindness, and acceleration of atherosclerotic processes. The combination of lowering the glucose levels in the blood and lowering the blood pressure may be most beneficial to patients that are at high risk to renal failure. The combination of these two effects with the lowering of  
5 cholesterol and LDL levels may be beneficial to patients that suffer from any combination of the four risk factors.

Fig. 9 is a graph of the development of serum-LDL optical density at 680nm during vortexing at a constant strength before licorice consumption, after licorice consumption, and after placebo consumption. The placebo was given for one  
10 month after the consumption of the licorice extract. The graph clearly shows that the LDL susceptibility to aggregation was lowered by the licorice consumption and returned to baseline level after licorice intake termination and placebo consumption.

Figure 10 shows the effect of licorice extract consumption on LDL retention. The results clearly show the LDL retention was significantly lowered  
15 thanks to the licorice extract consumption.

CLAIMS:

1. A pharmaceutical or nutraceutical preparation for lowering in human patients at least one of the following risk factors: blood pressure, blood glucose concentration, LDL susceptibility to retention, LDL susceptibility to aggregation, blood total cholesterol and LDL levels, and blood tryglicerides and VLDL concentration, said preparation comprising licorice extract which is water-insoluble and free from glycyrrhizinic acid.
2. A pharmaceutical or nutraceutical preparation according to claim 1 for lowering at least one of the following risk factors: blood pressure, blood glucose concentration, serum LDL susceptibility to aggregation and serum LDL susceptibility to retention.
3. A pharmaceutical or nutraceutical preparation according to claim 1 for lowering blood pressure and/or glucose concentration.
4. A pharmaceutical or nutraceutical preparation according to claim 1 for lowering LDL susceptibility to aggregation and LDL susceptibility to retention.
5. A pharmaceutical or nutraceutical preparation according to claim 1 for lowering blood glucose concentration.
6. A pharmaceutical or nutraceutical preparation according to claim 1 for treating inflammation.
7. A pharmaceutical or nutraceutical preparation according to claim 1 for lowering at least two of the following risk factors: blood pressure, blood glucose concentration, LDL susceptibility to retention, LDL susceptibility to aggregation, blood total cholesterol and LDL levels, and blood tryglicerides and VLDL concentration.
8. A pharmaceutical or nutraceutical preparation according to claim 7 for lowering both blood tryglicerides and LDL levels without significantly decreasing the HDL level.
9. A pharmaceutical or nutraceutical preparation comprising licorice extract, which is water insoluble and free from glycyrrhizinic acid, for use in the prevention

and/or treatment of at least one of the following conditions and diseases: atherosclerotic diseases, hypertension, cardiovascular diseases, chronic renal failure, carotid artery stenosis, coronary heart diseases, hypercholesterolemia, and hypertriglyceridemia.

- 5 10. The use of a licorice extract, which is ~~water-insoluble~~ and free from glycyrrhizinic acid, in the preparation of a medicament for preventing and/or treating at least one of the following conditions and diseases: inflammation, hypertension, diabetes, chronic renal failure, atherosclerotic diseases, cardiovascular diseases, carotid artery stenosis, and coronary heart diseases.
- 10 11. The use of a licorice extract, which is water-insoluble and free from glycyrrhizinic acid, in the preparation of an immuno-potentiator.
12. A method for treating atherosclerotic diseases, hypertension, cardiovascular diseases, chronic renal failure, carotid artery stenosis, and coronary heart diseases in a subject, comprising administering to said subject a  
15 therapeutically effective amount of a licorice extract that is water-insoluble and free of glycyrrhizinic acid.

For the Applicants,  
REINHOLD COHN AND PARTNERS  
BY:

S. Hirsch

1/10




FIG. 1

2/10

### Diastolic Blood Pressure




FIG. 2

3/10

Total Cholesterol




FIG. 3



4/10

### LDL Levels




FIG. 4

5/10




FIG. 5

6/10

### VLDL Concentration




FIG. 6

7/10

### Triglycerides Levels




FIG. 7

8/10




FIG. 8

9/10




FIG. 9

10/10

### LDL Retention




FIG. 10